Datavault AI Grants Scilex Exclusive License for AI-Driven Biotech Exchange Platform

Datavault AI (NASDAQ: DVLT) has granted Scilex Holding Company an exclusive worldwide license to deploy its proprietary AI-driven technology within the biotech and biopharma sectors. This strategic agreement enables Scilex to build and operate a Biotech Exchange platform designed to tokenize, trade, and monetize biotech assets including genomic data, diagnostics, and drug information. The licensing arrangement represents a significant expansion of Datavault AI's technology into the life sciences industry, leveraging the company's expertise in AI-driven blockchain solutions for data monetization and asset tokenization.

The financial terms of the agreement include a $10 million upfront payment structured in four installments, with potential milestone payments reaching up to $2.55 billion. This substantial financial framework underscores the significant market opportunity both companies see in applying AI and blockchain technology to biotech asset management. The technology is expected to expand beyond biotech into a comprehensive Pharmaceutical Exchange platform, addressing what Datavault AI estimates as a $2 trillion market opportunity. This expansion would provide pharmaceutical companies with new pathways to access non-dilutive funding through asset tokenization and secure data exchange.

Datavault AI's technology suite brings proven high-performance computing expertise and a broad patent portfolio to the biotech sector. The company's Information Data Exchange (IDE) platform enables Digital Twins and facilitates the licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata objects. This technology foundation supports responsible AI implementation with integrity, which is particularly crucial in the sensitive biotech and pharmaceutical industries where data security and provenance are paramount concerns.

The exclusive license agreement positions Scilex to revolutionize how biotech assets are managed, traded, and monetized in the emerging Web 3.0 environment. By tokenizing valuable biotech assets such as genomic data and drug information, the platform aims to create new liquidity opportunities for research institutions, pharmaceutical companies, and biotech firms. The technology's ability to provide comprehensive solutions with AI and Machine Learning automation, third-party integration, detailed analytics, and marketing automation makes it particularly suited for the complex requirements of the biotech industry. This partnership represents a significant step toward modernizing asset management and funding mechanisms in the life sciences sector through advanced AI and blockchain technologies.